ライフサイエンスコーパス: lanthionine

1 0,000x faster with L-histidine than with L,L-lanthionine.

2 of the two peptides of bicereucin contains a lanthionine.

3 ndenses two molecules of cysteine, generates lanthionine.

4 cose), followed by other cross-links such as lanthionine.

5 e, and CSE, but not CBS, efficiently cleaves lanthionine.

6 ety of orthogonally protected derivatives of lanthionine 1.

7 Lanthionine, a thioether analogue of cystine, is a key c

8 -OH (1d), where Ala(L) and Val(L) denote the lanthionine amino acid ends linked by a monosulfide brid

9 L7]-Thr8-NH2, where AlaL denotes each of the lanthionine amino acid ends linked by the monosulfide br

10 mutants, M. smegmatis strain PM440, utilizes lanthionine, an unusual bacterial metabolite, in place o

11 stability toward enzymatic degradation, the lanthionine analog has a 2.4 times longer half-life than

12 r peptide-bound dehydroalanine (Dha) to form lanthionine, analogous to the reaction catalyzed by LanC

13 PI and MVD assays revealed that the dimethyl lanthionine analogues 1b and 1d, denoted as D-Val(L) in

14 It contains one methyl-lanthionine and four lanthionine bridges and inhibits ce

15 d higher concentrations of lysinoalanine and lanthionine and lower concentrations of available lysine

16 Lanthipeptides contain lanthionine and methyllanthionine bis-amino acids that h

17 Lanthionine and methyllanthionine bridges, closing the m

18 he resulting unsaturated amino acids to form lanthionine and methyllanthionine bridges, respectively.

19 d that, like cytolysin, carnolysin contained lanthionine and methyllanthionine residues of unusual st

20 These polycyclic peptides contain lanthionine and methyllanthionine residues that result i

21 The stereochemistry of the lanthionine and methyllanthionine residues was determine

22 were established, and the topologies of the lanthionine and methyllanthionine rings were determined.

23 highly cyclized lantibiotic, containing six lanthionine and methyllanthionine rings, three of which

24 e discovery of lantibiotics with alternative lanthionine and methyllanthionine stereochemistry has pr

25 tack the dehydrated residues to generate the lanthionine and methyllanthionine thioether cross-linked

26 ationally modified, and are characterized by lanthionine and methyllanthionine thioether cross-links.

27 are characterized by the unique amino acids lanthionine and methyllanthionine, introduced by means o

28 sidues to generate the thioether cross-links lanthionine and methyllanthionine, respectively.

29 e of the thioether-containing bisamino acids lanthionine and methyllanthionine.

30 ence of the thioether-containing amino acids lanthionine and methyllanthionine.

31 tion of the thioether-containing amino acids lanthionine and methyllanthionine.

32 ications, including the thioether structures lanthionine and methyllanthionine.

33 ing the characteristic thioether cross-links lanthionine and methyllanthionine.

34 One dehydroalanine, one lanthionine and three beta-methyl-lanthionine residues w

35 ivaricins are polycyclic peptides containing lanthionine and/or beta-methyllanthionine residues produ

36 y cysteines to form cyclic thioethers termed lanthionines and methyllanthionines.

37 predicted to be virtually the sole source of lanthionine, and CSE, but not CBS, efficiently cleaves l

38 Lanthionine antibiotics are an important class of natura

39 ondensation of 2 mol of cysteine to generate lanthionine, are quantitatively less significant.

40 sted the proposal that LanCL1 is involved in lanthionine biosynthesis by constructing LanCL1 knock-ou

41 ting that LanCL proteins are not involved in lanthionine biosynthesis.

42 goadsporin, this dehydration is catalyzed by lanthionine biosynthetic enzyme B (LanB) or LanB-like pr

43 hree beta-methyl lanthionine bridges and one lanthionine bridge and demonstrated limited antibiotic a

44 of cyclic somatostatin analogs containing a lanthionine bridge have been subjected to studies of str

45 modification of sandostatin by introducing a lanthionine bridge resulted in a significantly increased

46 e amino acids in positions 7 and 27 form the lanthionine bridge, giving a globular conformation to th

47 isulfide group is replaced by a monosulfide (lanthionine) bridge (D-Phe1-c[AlaL2-Phe3-D-Trp4-Lys5-Thr

48 study we report the solid-phase synthesis of lanthionine-bridged analogues of ProTx-II, in which one

49 ive cyclization on resin to give the desired lanthionine-bridged peptide.

50 It contains one methyl-lanthionine and four lanthionine bridges and inhibits cell wall biosynthesis

51 However, SapT, which bears three beta-methyl lanthionine bridges and one lanthionine bridge and demon

52 The beta-methyl-lanthionine bridges are established between residues 12-

53 enzymes are proposed to create the hallmark lanthionine bridges.

54 tion of four dehydroalanine residues and two lanthionine bridges.

55 ws preparation of more than 10(11) different lanthionine containing peptides.

56 ed peptide bacteriocins called lantibiotics (lanthionine-containing antibiotics) and is produced by t

57 Lacticin 481 is a lanthionine-containing bacteriocin (lantibiotic) produce

58 Finally, the identification of a second lanthionine-containing morphogenetic peptide suggests th

59 Lanthionine-containing peptides (lanthipeptides) are a f

60 ynthesis in the oceans-produces many cyclic, lanthionine-containing peptides (lantipeptides).

61 The (methyl)lanthionine cross-links characteristic to lanthipeptides

62 responsible for the synthesis of thioether (lanthionine) cross-links within nascent polypeptide chai

63 y hypothesized that this enzyme may act as a lanthionine epimerase, but the authors found a very low

64 F. nucleatum synthesizes lanthionine for its peptidoglycan, rather than meso-2,6-

65 ilities of PM440 to grow without DAP and use lanthionine for peptidoglycan biosynthesis result from a

66 ences that determine the regioselectivity of lanthionine formation.

67 n and mine for similar activity in saturated lanthionine formation.

68 have also demonstrated that the synthesis of lanthionine from trityl-protected beta-iodoalanines is p

69 We also show that the lanthionine group is a good mimetic of beta-VI turns and

70 es had the (2S,3S,6R) configuration, and the lanthionines had the (2S,6R) configuration, irrespective

71 Lanthionine has been detected in human brain as the down

72 (1) of sandostatin (SMS 201,995) and several lanthionine hexa-, hepta-, and octapeptides was carried

73 ighly dependent on the presence of a (2S,6R)-lanthionine in the peptide and an active conformation of

74 We then used this orthogonally protected lanthionine in the solid-phase synthesis of an analogue

75 unobu reaction, that gave the single desired lanthionine, in complete regio- and diastereoselectivity

76 The most direct approaches to lanthionine involve the reaction of cysteine with an ala

77 Lanthionine ketimine (LK) represents a poorly understood

78 in human brain as the downstream metabolite lanthionine ketimine (LK), which has been shown to have

79 natural products defined by the presence of lanthionine (Lan) and methyllanthionine (MeLan) cross-li

80 They contain lanthionine (Lan) and methyllanthionine (MeLan) residues

81 ic peptides characterized by the presence of lanthionine (Lan) and/or methyllanthionine (MeLan).

82 They contain characteristic lanthionine (Lan) or methyllanthionine (MeLan) structure

83 characterized by the presence of one or more lanthionine (Lan) or methyllanthionine (MeLan) thioether

84 xidation of the sulfur-containing amino acid lanthionine, limiting their use.

85 dehydroalanine (Dha), dehydrobutyrine (Dhb), lanthionine (Ln), and methyllanthionine (MeLn), are poor

86 ively), glyoxal lysine dimer, lysinoalanine, lanthionine, lysine and arginine.

87 es of enkephalin analogues incorporating the lanthionine modification are presented.

88 The lanthionine octapeptide with C-terminal Thr-ol (1) showe

89 Similarly, the lanthionine octapeptide with the C-terminal Thr-NH2 resi

90 acterize the stereochemistry of five (methyl)lanthionines of different stereochemistry using a simple

91 e have explored two synthetic routes to give lanthionine, orthogonally protected with Alloc/allyl and

92 A green and efficient method for preparing lanthionine peptides by a highly chemoselective and ster

93 anine, one lanthionine and three beta-methyl-lanthionine residues were found in its 27 amino acid seq

94 ionally modified peptides containing (methyl)lanthionine residues.

95 This is the first time a synthetic lanthionine ring analogue of a lantibiotic has retained

96 providing access to the regioselectivity of lanthionine ring formation using high-resolution tandem

97 ly directed by the construction of the first lanthionine ring.

98 nalogues containing either desmethyl- or oxa-lanthionine rings confirm that the precise geometry of t

99 directional fashion, forming a total of four lanthionine rings in its HalA2 substrate.

100 osynthetic clusters, despite the presence of lanthionine rings in these compounds.

101 nd thioether amino acids that introduce five lanthionine rings into the target peptide.

102 The metabolic stability of lanthionine-sandostatin and sandostatin have been studie

103 llanthionine stereoisomers and two different lanthionine stereoisomers that have been reported in kno

104 s linked by a monosulfide bridge to form the lanthionine structure, were successfully carried out via

105 one S-transferase-mu (GST-mu) and GST-pi and lanthionine synthase C-like protein-1 (LanCL1).

106 and the presence of 77 other genes (CRISPR, lanthionine synthase, glutathione synthetase, catalase,

107 chlorosins are formed enzymatically by ProcM lanthionine synthetase and not by a nonenzymatic process

108 or-activated receptor gamma (PPAR gamma) and lanthionine synthetase C-like 2 (LANCL2) as molecular ta

109 In humans and mice, lanthionine synthetase C-like 2 (LANCL2) has been charac

110 Lanthionine synthetase C-like 2 (LANCL2) is an immunoreg

111 mall molecule that selectively activates the Lanthionine Synthetase C-like 2 (LANCL2) pathway, result

112 In this study, we identify the lanthionine synthetase C-like 2 (LanCL2) protein as a po

113 BT-11 is orally active and binds to lanthionine synthetase C-like 2 (LANCL2), a glutathione-

114 Lanthionine synthetase C-like 2 (LANCL2), a novel therap

115 ally active, gut restricted, and targets the lanthionine synthetase C-like 2 immunometabolic pathway.

116 volving peptide substrates, the prochlorosin lanthionine synthetase evolves under a strong purifying

117 erse sequences that are modified by a single lanthionine synthetase into lanthipeptides of different

118 the prochlorosin peptide substrates and the lanthionine synthetase suggests that structure diversifi

119 ently discovered glutathione-binding protein lanthionine synthetase-like protein-1.

120 us and diverse lanthipeptides using a single lanthionine synthetase.

121 cular basis of NHLP engagement with class II lanthionine synthetases (LanMs).

122 We demonstrate that several lanthionine synthetases catalyse highly selective anti-a

123 is most likely a plant homolog of bacterial lanthionine synthetases.

124 that also has 2 dangling carboxylate groups, lanthionine, to form (99m)Tc(CO)(3)(LAN), a new renal ra

125 n of the cytolysin subunits and detection of lanthionine-type post-translational modifications within

126 e allyl and Alloc groups of the incorporated lanthionine unit was followed by regio- and stereoselect

127 a new approach to the synthesis of protected lanthionine, using a novel variant of the Mitsunobu reac

128 Lanthionine was systematically replaced with diaminopime

129 as amino acid cross-links (lysinoalanine and lanthionine) was investigated in direct (DI) and indirec

130 ty of the peptide by replacing the sulfur in lanthionine with a methylene unit.